Cargando…
Treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases and/or leptomeningeal disease (ROSET-BM)
Therapeutic options for breast cancer patients with brain metastases (BM)/leptomeningeal carcinomatosis (LMC) are limited. Here, we report on the effectiveness and safety of trastuzumab deruxtecan (T-DXd) in human epidermal growth factor receptor 2-positive breast cancer patients with BM. Data were...
| Autores principales: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10567705/ https://www.ncbi.nlm.nih.gov/pubmed/37821514 http://dx.doi.org/10.1038/s41523-023-00584-5 |
| _version_ | 1785119190354493440 |
|---|---|
| author | Niikura, Naoki Yamanaka, Takashi Nomura, Hironori Shiraishi, Kazuhiro Kusama, Hiroki Yamamoto, Mitsugu Matsuura, Kazuo Inoue, Kenichi Takahara, Sachiko Kita, Shosuke Yamaguchi, Miki Aruga, Tomoyuki Shibata, Nobuhiro Shimomura, Akihiko Ozaki, Yuri Sakai, Shuji Kiga, Yoko Izutani, Tadahiro Shiosakai, Kazuhito Tsurutani, Junji |
| author_facet | Niikura, Naoki Yamanaka, Takashi Nomura, Hironori Shiraishi, Kazuhiro Kusama, Hiroki Yamamoto, Mitsugu Matsuura, Kazuo Inoue, Kenichi Takahara, Sachiko Kita, Shosuke Yamaguchi, Miki Aruga, Tomoyuki Shibata, Nobuhiro Shimomura, Akihiko Ozaki, Yuri Sakai, Shuji Kiga, Yoko Izutani, Tadahiro Shiosakai, Kazuhito Tsurutani, Junji |
| author_sort | Niikura, Naoki |
| collection | PubMed |
| description | Therapeutic options for breast cancer patients with brain metastases (BM)/leptomeningeal carcinomatosis (LMC) are limited. Here, we report on the effectiveness and safety of trastuzumab deruxtecan (T-DXd) in human epidermal growth factor receptor 2-positive breast cancer patients with BM. Data were analyzed for 104 patients administered T-DXd. Overall response rate (ORR), progression-free survival (PFS), overall survival (OS), intracranial (IC)-ORR, and IC-PFS were evaluated. ORR by investigator assessment was 55.7% (total population). Median PFS was 16.1 months; 12-month OS rate was 74.9% (total population). Median time-to-treatment failure was 9.7 months. In 51 patients with BM imaging, IC-ORR and median IC-PFS by independent central review were 62.7% and 16.1 months, respectively. In 19 LMC patients, 12-month PFS and OS rates were 60.7% and 87.1%, respectively. T-DXd showed effectiveness regarding IC-ORR, IC-PFS, PFS, and OS in breast cancer patients with BM/active BM, and sustained systemic and central nervous system disease control in LMC patients. Trial Registration: UMIN000044995. |
| format | Online Article Text |
| id | pubmed-10567705 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-105677052023-10-13 Treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases and/or leptomeningeal disease (ROSET-BM) Niikura, Naoki Yamanaka, Takashi Nomura, Hironori Shiraishi, Kazuhiro Kusama, Hiroki Yamamoto, Mitsugu Matsuura, Kazuo Inoue, Kenichi Takahara, Sachiko Kita, Shosuke Yamaguchi, Miki Aruga, Tomoyuki Shibata, Nobuhiro Shimomura, Akihiko Ozaki, Yuri Sakai, Shuji Kiga, Yoko Izutani, Tadahiro Shiosakai, Kazuhito Tsurutani, Junji NPJ Breast Cancer Article Therapeutic options for breast cancer patients with brain metastases (BM)/leptomeningeal carcinomatosis (LMC) are limited. Here, we report on the effectiveness and safety of trastuzumab deruxtecan (T-DXd) in human epidermal growth factor receptor 2-positive breast cancer patients with BM. Data were analyzed for 104 patients administered T-DXd. Overall response rate (ORR), progression-free survival (PFS), overall survival (OS), intracranial (IC)-ORR, and IC-PFS were evaluated. ORR by investigator assessment was 55.7% (total population). Median PFS was 16.1 months; 12-month OS rate was 74.9% (total population). Median time-to-treatment failure was 9.7 months. In 51 patients with BM imaging, IC-ORR and median IC-PFS by independent central review were 62.7% and 16.1 months, respectively. In 19 LMC patients, 12-month PFS and OS rates were 60.7% and 87.1%, respectively. T-DXd showed effectiveness regarding IC-ORR, IC-PFS, PFS, and OS in breast cancer patients with BM/active BM, and sustained systemic and central nervous system disease control in LMC patients. Trial Registration: UMIN000044995. Nature Publishing Group UK 2023-10-11 /pmc/articles/PMC10567705/ /pubmed/37821514 http://dx.doi.org/10.1038/s41523-023-00584-5 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Article Niikura, Naoki Yamanaka, Takashi Nomura, Hironori Shiraishi, Kazuhiro Kusama, Hiroki Yamamoto, Mitsugu Matsuura, Kazuo Inoue, Kenichi Takahara, Sachiko Kita, Shosuke Yamaguchi, Miki Aruga, Tomoyuki Shibata, Nobuhiro Shimomura, Akihiko Ozaki, Yuri Sakai, Shuji Kiga, Yoko Izutani, Tadahiro Shiosakai, Kazuhito Tsurutani, Junji Treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases and/or leptomeningeal disease (ROSET-BM) |
| title | Treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases and/or leptomeningeal disease (ROSET-BM) |
| title_full | Treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases and/or leptomeningeal disease (ROSET-BM) |
| title_fullStr | Treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases and/or leptomeningeal disease (ROSET-BM) |
| title_full_unstemmed | Treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases and/or leptomeningeal disease (ROSET-BM) |
| title_short | Treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases and/or leptomeningeal disease (ROSET-BM) |
| title_sort | treatment with trastuzumab deruxtecan in patients with her2-positive breast cancer and brain metastases and/or leptomeningeal disease (roset-bm) |
| topic | Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10567705/ https://www.ncbi.nlm.nih.gov/pubmed/37821514 http://dx.doi.org/10.1038/s41523-023-00584-5 |
| work_keys_str_mv | AT niikuranaoki treatmentwithtrastuzumabderuxtecaninpatientswithher2positivebreastcancerandbrainmetastasesandorleptomeningealdiseaserosetbm AT yamanakatakashi treatmentwithtrastuzumabderuxtecaninpatientswithher2positivebreastcancerandbrainmetastasesandorleptomeningealdiseaserosetbm AT nomurahironori treatmentwithtrastuzumabderuxtecaninpatientswithher2positivebreastcancerandbrainmetastasesandorleptomeningealdiseaserosetbm AT shiraishikazuhiro treatmentwithtrastuzumabderuxtecaninpatientswithher2positivebreastcancerandbrainmetastasesandorleptomeningealdiseaserosetbm AT kusamahiroki treatmentwithtrastuzumabderuxtecaninpatientswithher2positivebreastcancerandbrainmetastasesandorleptomeningealdiseaserosetbm AT yamamotomitsugu treatmentwithtrastuzumabderuxtecaninpatientswithher2positivebreastcancerandbrainmetastasesandorleptomeningealdiseaserosetbm AT matsuurakazuo treatmentwithtrastuzumabderuxtecaninpatientswithher2positivebreastcancerandbrainmetastasesandorleptomeningealdiseaserosetbm AT inouekenichi treatmentwithtrastuzumabderuxtecaninpatientswithher2positivebreastcancerandbrainmetastasesandorleptomeningealdiseaserosetbm AT takaharasachiko treatmentwithtrastuzumabderuxtecaninpatientswithher2positivebreastcancerandbrainmetastasesandorleptomeningealdiseaserosetbm AT kitashosuke treatmentwithtrastuzumabderuxtecaninpatientswithher2positivebreastcancerandbrainmetastasesandorleptomeningealdiseaserosetbm AT yamaguchimiki treatmentwithtrastuzumabderuxtecaninpatientswithher2positivebreastcancerandbrainmetastasesandorleptomeningealdiseaserosetbm AT arugatomoyuki treatmentwithtrastuzumabderuxtecaninpatientswithher2positivebreastcancerandbrainmetastasesandorleptomeningealdiseaserosetbm AT shibatanobuhiro treatmentwithtrastuzumabderuxtecaninpatientswithher2positivebreastcancerandbrainmetastasesandorleptomeningealdiseaserosetbm AT shimomuraakihiko treatmentwithtrastuzumabderuxtecaninpatientswithher2positivebreastcancerandbrainmetastasesandorleptomeningealdiseaserosetbm AT ozakiyuri treatmentwithtrastuzumabderuxtecaninpatientswithher2positivebreastcancerandbrainmetastasesandorleptomeningealdiseaserosetbm AT sakaishuji treatmentwithtrastuzumabderuxtecaninpatientswithher2positivebreastcancerandbrainmetastasesandorleptomeningealdiseaserosetbm AT kigayoko treatmentwithtrastuzumabderuxtecaninpatientswithher2positivebreastcancerandbrainmetastasesandorleptomeningealdiseaserosetbm AT izutanitadahiro treatmentwithtrastuzumabderuxtecaninpatientswithher2positivebreastcancerandbrainmetastasesandorleptomeningealdiseaserosetbm AT shiosakaikazuhito treatmentwithtrastuzumabderuxtecaninpatientswithher2positivebreastcancerandbrainmetastasesandorleptomeningealdiseaserosetbm AT tsurutanijunji treatmentwithtrastuzumabderuxtecaninpatientswithher2positivebreastcancerandbrainmetastasesandorleptomeningealdiseaserosetbm |